{"protocolSection":{"identificationModule":{"nctId":"NCT00299416","orgStudyIdInfo":{"id":"HSC- MS-02-188"},"secondaryIdInfos":[{"id":"P50NS44277 project #1"}],"organization":{"fullName":"The University of Texas Health Science Center, Houston","class":"OTHER"},"briefTitle":"Caffeinol Hypothermia Protocol","officialTitle":"Combined Neuroprotective Modalities Coupled With Thrombolysis in Acute Ischemic Stroke: A Pilot Study of Caffeinol and Mild Hypothermia"},"statusModule":{"statusVerifiedDate":"2011-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-02"},"primaryCompletionDateStruct":{"date":"2009-01","type":"ACTUAL"},"completionDateStruct":{"date":"2009-08","type":"ACTUAL"},"studyFirstSubmitDate":"2006-03-02","studyFirstSubmitQcDate":"2006-03-02","studyFirstPostDateStruct":{"date":"2006-03-06","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-08-16","resultsFirstSubmitQcDate":"2011-04-05","resultsFirstPostDateStruct":{"date":"2011-05-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-04-05","lastUpdatePostDateStruct":{"date":"2011-05-03","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"James C. Grotta, MD-","oldOrganization":"UT- Houston Health Science Center, Department of Neurology"},"leadSponsor":{"name":"The University of Texas Health Science Center, Houston","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Caffeinol is a combination of caffeine and alcohol. The amount given is about the same as 1-2 glasses of wine and 3-4 cups of coffee. The patient receives a one time dose given over two hour while being cooled to 34.5 C."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Stroke","Nonhemorrhagic","hypothermia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ACTUAL"}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"Caffeinol","description":"Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours."},{"type":"PROCEDURE","name":"hypothermia","description":"External or internal cooling for 24 hours and rewarming over 12 hours."}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Symptomatic Intracerebral Hemorrhage","description":"Symptomatic intracerebral hemorrhages were measured by a full NIHSS(National Institute of Health Stroke Scale) prior to caffeinol \\& hypothermia,at the end of hypothermia \\& rewarming, 24 hrs after stroke onset, daily during hospitalization,\\& at the 90 day follow-up visit. In addition, modified NIHSS were done hourly during the 24 hr hypothermia period \\& 12 hr rewarming period. At the end of rewarming an MRI was obtained to verify if hemorrhages or neurologic deteriorations were present.NIHSS scores severity of stroke on 11 items;more points given for greater deficiencies(range 0-42,0=normal)","timeFrame":"from pre-dosage to 90 day followup"},{"measure":"Number of Participants With Catheter Related Complications During Hypothermia & Rewarming","description":"Catheter-related complications assessed whether participants had bleeding (major hemorrhaging) that required a blood transfusion, this was determined by labs. Participants were monitored for infections every hour during vital signs in the 24 hour hypothermia phase and 12 hour rewarming phase.","timeFrame":"over 36 hour period"},{"measure":"Number of Participants With Cardiorespiratory Failure","description":"The possibility of cardiorespiratory failure was monitored every 30 minutes during the 24 hour hypothermia period based on vitals signs and oxygen saturation.","timeFrame":"every 30 minutes during hypothermia induction"}],"secondaryOutcomes":[{"measure":"Feasibility: Time Required to Reach the Target Core Temperature or Lowest Tolerated Temperature, Stability of Patient Temperature, Control of Rewarming,","description":"Hypothermia will be maintained for 24 hours, afterward, the patient will be rewarmed, gradually, over 12 hours to 36.5C.","timeFrame":"rewarming over 12 hours until 36.5C has been achieved"},{"measure":"Achievement of Therapeutic Serum Ethanol and Caffeine Levels, and Amount of Sedation Needed to Suppress Shivering.","timeFrame":"rewarming over 12 hours until 36.5C has been achieved"},{"measure":"Efficacy: NIHSS < 2 at 24 Hours, Modified Rankin Scale (mRS) < 2 at 3 Months, NIHSS < 2 at 3 Months, and Length of Hospital and ICU Stay.","description":"NIHSS score of ≤ 2 24 hours after stroke onset modified Rankin Scale (mRS) \\< 2 at 90 day followup NIHSS score of ≤ 2 at daily duration of hospitalization and ICU stay and 90 day follow up.","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 18-80 years\n2. Clinical presentation of acute ischemic stroke\n3. Computed tomography (CT) scan compatible with acute ischemic stroke.\n4. Time to caffeinol treatment \\< 240 minutes from stroke onset.\n5. Time to hypothermia initiation \\< 300 minutes from stroke onset.\n6. Presumed cortical location of stroke (must have at least on sign such as aphasia, neglect, visual field cut)\n7. National Institutes of Health Stroke Scale (NIHSS) \\> 8 at time of each treatment.\n8. Tissue plasminogen activator (TPA) treated patients must meet all established criteria for TPA.\n\nExclusion Criteria:\n\n1. Etiology other than ischemic stroke.\n2. Item 1a on NIHSS \\> 1\n3. Signs/symptoms of subcortical, brainstem or cerebellar stroke.\n4. Symptoms resolving or NIHSS \\< 8 at time of each treatment.\n5. NIHSS \\> 20 if right hemisphere or \\>25 if left hemisphere\n6. Known alcoholic\n7. Clinical or laboratory evidence of alcohol intoxication.\n8. Historical evidence of exogenous caffeine exposure beyond daily consumption of coffee or soft drinks.\n9. Known hematologic dyscrasias that affect thrombosis.\n10. Comorbid conditions likely to complicate therapy:\n\n    1. End-stage cardiomyopathy\n    2. Uncompensated or clinically significant arrhythmia\n    3. Myopathy\n    4. Liver disease\n    5. History of pelvic or abdominal mass likely to compress inferior vena cava.\n    6. End-stage AIDS\n    7. History of clinically significant gastrointestinal (GI) bleeding\n    8. Impaired renal function with creatinine clearance, 50 ml/min\n11. Intracerebral / intraventricular hemorrhage\n12. Systolic blood pressure (SBP) \\> 210 or \\< 100; diastolic blood pressure (DBP) \\> 100 or \\< 50 mmHg\n13. Severe coagulopathy\n14. Pregnancy\n15. Use of monoamine oxidase inhibitor (MAOI),serotonin-specific reuptake inhibitor (SSRI) or Tricyclic Antidepressants (TCA) within the preceding 2 weeks\n16. Known history of epilepsy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"James C. Grotta, MD","affiliation":"The University of Texas Health Science Center, Houston","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Memorial Hermann Hospital - Medical Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Open label pilot trial; Caffeinol Arm","recruitmentDetails":"Patient/\\& or family was approached by one of the investigators in the Emergency Department in order to obtain informed consent.","groups":[{"id":"FG000","title":"Caffeinol","description":"Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"30"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Caffeinol","description":"Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"28"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54.7","spread":"15.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"18"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"12"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Symptomatic Intracerebral Hemorrhage","description":"Symptomatic intracerebral hemorrhages were measured by a full NIHSS(National Institute of Health Stroke Scale) prior to caffeinol \\& hypothermia,at the end of hypothermia \\& rewarming, 24 hrs after stroke onset, daily during hospitalization,\\& at the 90 day follow-up visit. In addition, modified NIHSS were done hourly during the 24 hr hypothermia period \\& 12 hr rewarming period. At the end of rewarming an MRI was obtained to verify if hemorrhages or neurologic deteriorations were present.NIHSS scores severity of stroke on 11 items;more points given for greater deficiencies(range 0-42,0=normal)","populationDescription":"Number of participants were determined by intention to treat. We did not use any imputation technique.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"from pre-dosage to 90 day followup","groups":[{"id":"OG000","title":"Caffeinol","description":"Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Feasibility: Time Required to Reach the Target Core Temperature or Lowest Tolerated Temperature, Stability of Patient Temperature, Control of Rewarming,","description":"Hypothermia will be maintained for 24 hours, afterward, the patient will be rewarmed, gradually, over 12 hours to 36.5C.","reportingStatus":"NOT_POSTED","paramType":"NUMBER","unitOfMeasure":"participants with acute ischemic stroke","timeFrame":"rewarming over 12 hours until 36.5C has been achieved"},{"type":"SECONDARY","title":"Achievement of Therapeutic Serum Ethanol and Caffeine Levels, and Amount of Sedation Needed to Suppress Shivering.","reportingStatus":"NOT_POSTED","paramType":"NUMBER","unitOfMeasure":"participants with acute ischemic stroke","timeFrame":"rewarming over 12 hours until 36.5C has been achieved"},{"type":"SECONDARY","title":"Efficacy: NIHSS < 2 at 24 Hours, Modified Rankin Scale (mRS) < 2 at 3 Months, NIHSS < 2 at 3 Months, and Length of Hospital and ICU Stay.","description":"NIHSS score of ≤ 2 24 hours after stroke onset modified Rankin Scale (mRS) \\< 2 at 90 day followup NIHSS score of ≤ 2 at daily duration of hospitalization and ICU stay and 90 day follow up.","reportingStatus":"NOT_POSTED","paramType":"NUMBER","unitOfMeasure":"participants with acute ischemic stroke","timeFrame":"90 days"},{"type":"PRIMARY","title":"Number of Participants With Catheter Related Complications During Hypothermia & Rewarming","description":"Catheter-related complications assessed whether participants had bleeding (major hemorrhaging) that required a blood transfusion, this was determined by labs. Participants were monitored for infections every hour during vital signs in the 24 hour hypothermia phase and 12 hour rewarming phase.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"over 36 hour period","groups":[{"id":"OG000","title":"Caffeinol","description":"Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Cardiorespiratory Failure","description":"The possibility of cardiorespiratory failure was monitored every 30 minutes during the 24 hour hypothermia period based on vitals signs and oxygen saturation.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"every 30 minutes during hypothermia induction","groups":[{"id":"OG000","title":"Caffeinol","description":"Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse event data was collected over the duration of the study (2003-2009)","eventGroups":[{"id":"EG000","title":"Caffeinol","description":"Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg.","seriousNumAffected":9,"seriousNumAtRisk":30,"otherNumAffected":17,"otherNumAtRisk":30}],"seriousEvents":[{"term":"Death","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Three patients died (SAE unrelated to study interventions):\n\n(1) symptomatic hemorrhage due to severity of stroke\n\n(1) malignant edema/ herniation\n\n(1) unrelated medical condition (withdrawal of care requested by family)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30}]},{"term":"Neuroworsening","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30}]},{"term":"Cholecysitits","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30}]},{"term":"Reduced respiratory drive","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30}]},{"term":"Parenchymal hemorrhage","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"3 symptomatic\n\n1 asymptomatic","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30}]},{"term":"Thrombotic thrombocytopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Attributed to clopidrogrel and required treatment with plasmapheresis","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30}]}],"otherEvents":[{"term":"Sedation","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Sedation noted:\n\n* (2)Demerol dose was reduced/held. Sedation resolved.\n* (2)Acidosis secondary to sedation. Treated/ resolved.","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30}]},{"term":"Elevated CK","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Elevated Ck noted -asymptomatic/ resolved","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":30}]},{"term":"Elevated Amylase","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Elevated amylase noted:Asymptomatic/resolved.","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30}]},{"term":"Device failure","organSystem":"Surgical and medical procedures","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Cooling machine failure (3) Icy catheter tubing leak (1)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30}]},{"term":"Asymptomatic hemorrhagic transformation","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Noted/ resolved","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":30}]},{"term":"Elevated WBC","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"No fever/ symptoms; resolved without treatment.","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"(1)Treated with lasix and nebulizer treatment. Resolved.\n\n(1)Shortness of breath, oxygen saturation 87%, infiltrates on CXR. Treated with BiPAP \\& lasix","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30}]},{"term":"Infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"* (2)UTI treated/ resolved.\n* GNR central line infection. Line removed/ antibiotic added. Resolved.\n* MRSA pneumonia treated.\n* Possible pneumonia treated with naficillin/ ceftin.\n* Pneumonia treated with antibiotics. Resolved.","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30}]},{"term":"Low Hgb/ Hct","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30}]},{"term":"Abnormal Labs (chem.)","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"(1)Low K+ - replaced/ resolved\n\n(1)Elevated K+ - treated\n\n(1)Elevated Mg - asymptomatic/ resolved","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"(1) A. fib\n\n(1)A. fib with AV block","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"James C. Grotta, MD","organization":"UT-Houston Health Science Center, Department of Neurology","email":"james.c.grotta@uth.tmc.edu","phone":"713-500-7088"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007035","term":"Hypothermia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001832","term":"Body Temperature Changes"}],"browseLeaves":[{"id":"M9775","name":"Hypothermia","asFound":"Hypothermia","relevance":"HIGH"},{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4801","name":"Body Temperature Changes","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M3467","name":"Ethanol","relevance":"LOW"},{"id":"M5063","name":"Caffeine","relevance":"LOW"},{"id":"T370","name":"Caffeine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CNSSti","name":"Central Nervous System Stimulants"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":true}